Lund, Sweden, 2014-11-19 08:53 CET (GLOBE NEWSWIRE) --
EXINI Diagnostics AB has signed a collaboration agreement with DexTech Medical AB as to a clinical phase-II study with the candidate drug OsteoDex. The agreement demonstrates the significance of BSI (Bone Scan Index) as a biomarker in the evaluation process of novel therapies for treating advanced prostate cancer with bone metastases.
The objective is to monitor the progression of bone-metastatic disease in castration-resistant prostate cancer patients, utilizing the software package EXINI boneBSI in a clinical phase-II study of a new drug compound against bone metastases.
”We believe the technology developed by EXINI will enable more objective and valuable information to be extracted from the bone scan examinations planned”, comments Anders Holmberg, CEO, DexTech Medical AB.
”Entering yet another collaboration around the use of BSI in clinical drug development is very positive for us”, says Eva Bondesson, Medical Affairs Director, EXINI Diagnostics AB.
Read more:
www.exini.com
www.dextechmedical.com
www.bonescanindex.org
Or, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
